A loss of c-kit expression is associated with an advanced stage and poor prognosis in breast cancer

被引:43
作者
Tsutsui, S.
Yasuda, K.
Suzuki, K.
Takeuchi, H.
Nishizaki, T.
Higashi, H.
Era, S.
机构
[1] Matsuyama Red Cross Hosp, Dept Breast Surg, Matsuyama, Ehime 7908524, Japan
[2] Beppu Med Ctr, Dept Surg, Beppu, Oita, Japan
[3] Matsuyama Red Cross Hosp, Dept Surg, Matsuyama, Ehime 7908524, Japan
[4] Beppu Med Ctr, Dept Pathol, Beppu, Oita, Japan
关键词
breast cancer; c-kit; prognosis;
D O I
10.1038/sj.bjc.6603183
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
To evaluate the c-kit expression in breast cancer, 217 invasive ductal carcinomas of the breast were immunohistochemically stained for c-kit protein. The c-kit expression was positive in 59 (27%) of 217 tumours, while the c-kit expression was negative in 158 (73%) of 217 tumours. There was a significant correlation between a negative expression of the c-kit protein and lymph node metastasis (P < 0.0001), and the incidence of a negative expression of the c-kit protein increased as the number of the metastatic lymph nodes increased (P=0.0003). The c-kit expression did not significantly correlate with the tumour size, nuclear grade, oestrogen receptor status, MIB-1 counts and p53 protein expression. A univariate analysis indicated the patients with the negative c-kit expression to have a worse disease-free survival (DFS) than those with the positive c-kit expression (P=0.0041), while a multivariate analysis determined lymph node metastases and the MIB-1 counts to be independently significant factors for DFS. In conclusion, a loss of the c-kit expression was found in about three-fourth of invasive ductal carcinoma of the breast and was associated with lymph node metastases. The prognostic implications of the c-kit expression seem to be due to fact that a loss of the c-kit expression is associated with an advanced stage of breast cancer.
引用
收藏
页码:1874 / 1878
页数:5
相关论文
共 29 条
[1]   Expression of HER2 and C-KIT in nasopharyngeal carcinoma: Implications for a new therapeutic approach [J].
Bar-Sela, G ;
Kuten, A ;
Ben-Eliezer, S ;
Gov-Ari, E ;
Ben-Izhak, O .
MODERN PATHOLOGY, 2003, 16 (10) :1035-1040
[2]   Immunohistochemical expression of the c-kit proto-oncogene product in human malignant and non-malignant breast tissues [J].
Chui, X ;
Egami, H ;
Yamashita, J ;
Kurizaki, T ;
Ohmachi, H ;
Yamamoto, S ;
Ogawa, M .
BRITISH JOURNAL OF CANCER, 1996, 73 (10) :1233-1236
[3]   CD 117 (KIT): A diverse protein with selective applications in surgical pathology [J].
Gibson, PC ;
Cooper, K .
ADVANCES IN ANATOMIC PATHOLOGY, 2002, 9 (01) :65-69
[4]  
HINES SJ, 1995, CELL GROWTH DIFFER, V6, P769
[5]   Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors [J].
Hirota, S ;
Isozaki, K ;
Moriyama, Y ;
Hashimoto, K ;
Nishida, T ;
Ishiguro, S ;
Kawano, K ;
Hanada, M ;
Kurata, A ;
Takeda, M ;
Tunio, GM ;
Matsuzawa, Y ;
Kanakura, Y ;
Shinomura, Y ;
Kitamura, Y .
SCIENCE, 1998, 279 (5350) :577-580
[6]   The meaning of the c-kit proto-oncogene product in malignant transformation in human mammary epithelium [J].
Ko, CD ;
Kim, JS ;
Ko, BG ;
Son, BH ;
Kang, HJ ;
Yoon, HS ;
Cho, EY ;
Gong, GY ;
Ahn, SH .
CLINICAL & EXPERIMENTAL METASTASIS, 2003, 20 (07) :593-597
[7]   Expression of the c-kit receptor characterizes a subset of neuroblastomas with favorable prognosis [J].
Krams, M ;
Parwaresch, R ;
Sipos, B ;
Heidorn, K ;
Harms, D ;
Rudolph, P .
ONCOGENE, 2004, 23 (02) :588-595
[8]   EXPRESSION OF C-KIT AND KIT-LIGAND PROTEINS IN NORMAL HUMAN TISSUES [J].
LAMMIE, A ;
DROBNJAK, M ;
GERALD, W ;
SAAD, A ;
COTE, R ;
CORDONCARDO, C .
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 1994, 42 (11) :1417-1425
[9]  
MATSUDA R, 1993, AM J PATHOL, V142, P339
[10]   KIT expression in fetal, normal adult, and neoplastic renal tissues [J].
Miliaras, D ;
Karasavvidou, F ;
Papanikolaou, A ;
Sioutopoulou, D .
JOURNAL OF CLINICAL PATHOLOGY, 2004, 57 (05) :463-466